

**Press release: Banque Delubac & Cie - Corporate & Investment Bank**

**Banque Delubac & Cie supports the Seventure fund and the Biomatlante founders, a company specialising in the manufacture and marketing of synthetic bone substitutes, in the sale of their securities to the British group Advanced Medical Solutions Group (listed on the London Stock Exchange).**



The listed group Advanced Medical Solutions Group plc (AIM: AMS), which specialises in the design, development and manufacture of surgical dressings and medical care materials, has completed the acquisition of Biomatlante SA, the French specialist in biomaterials

The objective of this acquisition is to strengthen the product portfolio, the R&D pipeline and the positioning of AMS in the market. It allows the group to integrate a range of cutting-edge surgical products and to strengthen its R&D centre in complementary surgical technologies, thereby opening up new opportunities on a surgery market worth an estimated \$ 0.5 billion.

The biomaterials developed by Biomatlante are mainly sold in France and the Netherlands and complete the AMS surgical product portfolio. The acquisition of Biomatlante by AMS will accelerate product sales thanks to complementary distribution networks and geographic presence.

The R&D pipeline and technological platforms acquired by AMS therefore make it possible to broaden the Group's offer of bio-surgical products while generating multiple synergies at commercial, marketing, operational and regulatory levels.

Biomatlante has a patented technological platform, offering a wide range of biomaterials used in orthopaedic, spine, dental and sports surgery, as well as a portfolio of new generation products under development. The products marketed by the company are sold in more than 50 countries around the world and include synthetic bone substitutes, collagen membranes and bio absorbable screws.

Biomatlante is ISO 13485 and MDSAP certified. Its technology has been cited in numerous clinical studies. The company is positioned to meet the obligations arising from the new European regulation on medical devices ("MDR").

*"This acquisition is in line with our strategy of developing new technologies complementary to our surgical products portfolio and allows us to take advantage of our global access to the market. It also gives AMS access to many new markets, including the market for synthetic bone substitutes which is worth an estimated \$ 0.5 billion. We are delighted to welcome the Biomatlante team to AMS and look forward to collaborating with them to accelerate their worldwide commercial success. This operation will continue to develop Biomatlante technologies in a multitude of new applications and indications"* explains Chris Meredith, CEO of AMS.

*“We were very pleased to advise Biomatlante's shareholders in their strategic merger with AMS, generating synergies, for both Biomatlante - which will accelerate its growth thanks to AMS distribution networks - and for AMS, which is accessing a complementary market to its current surgical products range and an R&D pipeline to develop new generation products”* says Christine Lambert-Goué, Director, Banque Delubac & Cie Corporate & Investment Bank.

*“This transaction once again demonstrates the ability of our team to advise managers and shareholders in their M&A operations, both in France and with foreign counterparts”* explains Mickaël Hazout, Managing Director Banque Delubac & Cie Corporate & Investment Bank.

**As part of this transaction, Banque Delubac & Cie advised and successfully supported the Seventure fund as well as the founding shareholders in the preparation of the sale of Biomatlante, the search for potential buyers, both in Europe and internationally, up until final negotiations.**

### **About Banque Delubac & Cie**

Banque Delubac & Cie, created in 1924, is an independent financial institution offering specialised banking and financial services. Employing more than 200 employees, it has branches in Paris, Lyon, Toulouse, Valence and Le Cheylard (historic head office, located in Ardèche).

Over the last 10 years its Corporate & Investment Bank division has developed a merger and acquisition advisory, engineering and financial operations activity for listed and unlisted companies).

For more information: <https://www.delubac.com/>

### **About Biomatlante**

A pioneer in biomaterials, Biomatlante develops, manufactures and markets synthetic bone substitute technologies.

Biomatlante specialises in the production of synthetic biomaterials that promote bone regeneration and today is one of the world leaders in bone grafting technologies. It sells its products in more than 50 countries. Biomatlante products are commonly used in orthopedic, trauma, spine, ENT, maxillofacial and dental surgery.

Biomatlante works closely with universities and research centres around the world. It collaborates notably with the CNRS (French Centre for Scientific Research), INSERM (French National Institute of Health and Medical Research) and several other national and international universities. These partnerships strengthen Biomatlante's ability to be at the forefront of innovation in new biomaterials.

MBCP® technology is a synthetic bone substitute platform for biphasic calcium phosphate with a unique micro and macroporous structure that most closely resembles the architecture of natural human bone. MBCP® Technology products are available in different forms (granules, blocks and anatomical shapes), injectable / mouldable sealant, absorbable osteosynthesis (based on specific composite material combining granules and MBCP® polymers), and an intelligent MBCP® + insert for tissue engineering which can be combined with bone marrow or stem cells. The osteogenic and osteoinductive properties are scientifically proven and linked to the bioactive Biomatlante technology. The EZ-Cure® collagen membrane, a product complementary to the bone filling ranges, is offered to dental surgeons and provides a complete solution in maxillofacial surgery.

For more information: <https://biomatlante.com/fr/>

**Transaction advisors:**

**Legal advice for the transferor**

*Gueguen Avocats*

Sonia Nicolaë - Lawyer Managing Partner

Jalila Bahmed - Lawyer

*Racine Avocats*

Yohan Jabbour Gédéon – Lawyer Counsel

**M&A advice for the transferor**

*Banque Delubac & Cie*

Mickaël Hazout – CIB Managing Director - [mickael.hazout@delubac.fr](mailto:mickael.hazout@delubac.fr)

Christine Lambert-Goue – CIB Director – [christine.lambertgoue@delubac.fr](mailto:christine.lambertgoue@delubac.fr)

Arthur Libier - CIB Analyst - [arthur.libier@delubac.fr](mailto:arthur.libier@delubac.fr)

**Other advice**

AMS financial audit: PwC Transaction Services

AMS Legal Advice: Cancel Avocats – Christophe Cancel